Department of Pharmacology, School of Pharmacy, China Pharmaceutical University, Longmian Avenue, 639, Nanjing, Jiangsu, 211198, China; Shanghai Jiao Tong University, School of Pharmacy, 800 Dongchuan Road, Shanghai, 200240, China.
Department of Pharmacology, School of Pharmacy, China Pharmaceutical University, Longmian Avenue, 639, Nanjing, Jiangsu, 211198, China.
Biomed Pharmacother. 2018 Oct;106:1734-1741. doi: 10.1016/j.biopha.2018.07.107. Epub 2018 Jul 30.
Antioxidant therapy is considered as promising strategy for treating oxidative stress-induced cardiovascular disease. Bis (β-elemene-13-yl) glutarate (BEG) is a novel β-elemene derivative. Herein, we examined the antioxidant activity of BEG on human umbilical vein endothelial cells (HUVECs) after injury with hydrogen peroxide (HO) and investigated the mechanism involved. HUVECs were divided into the following groups: control group (untreated cells); treated groups (cells treated with 0.1, 1, 10 μmol/L of BEG); positive control group (cells treated with 0.1 mM Vitamin E); model group (cells treated with 0.5 mM HO alone). Cells were pre-incubated with or without BEG for 24 h and then incubated for a further 2 h with 0.5 mM HO. Our results showed that BEG significantly reduced HO induced loss in endothelial cell viability, reactive oxygen species (ROS) production, reduced lactate dehydrogenase (LDH) release, and malonyldialdehyde (MDA) level in a concentration-dependent manner. Also, BEG increased the cellular the superoxide dismutase (SOD) activity. Moreover, we found that HO decreased Akt and eNOS phosphorylation, which perhaps, indirectly reduced nitric oxide (NO) production. These effects induced by HO, however, were reduced by pre-treatment with BEG. BEG effects were inhibited by a PI3K inhibitor (wortmannin) and eNOS inhibitor (L-NAME). In conclusion, the present study demonstrated that BEG has antioxidant activity. Furthermore, BEG reduced HO-induced endothelial cells injury by the involvement of antioxidation and PI3K/Akt/eNOS/NO signaling pathways.
抗氧化治疗被认为是治疗氧化应激诱导的心血管疾病的有前途的策略。双(β-榄香烯-13-基)戊二酸酯(BEG)是一种新型的β-榄香烯衍生物。本文研究了 BEG 在过氧化氢(HO)损伤后人脐静脉内皮细胞(HUVEC)中的抗氧化活性,并探讨了其相关机制。将 HUVEC 分为以下几组:对照组(未处理的细胞);处理组(分别用 0.1、1、10 μmol/L 的 BEG 处理的细胞);阳性对照组(用 0.1 mM 维生素 E 处理的细胞);模型组(单独用 0.5 mM HO 处理的细胞)。细胞先用或不用 BEG 孵育 24 h,然后再用 0.5 mM HO 孵育 2 h。结果显示,BEG 可显著降低 HO 诱导的内皮细胞活力丧失、活性氧(ROS)产生、乳酸脱氢酶(LDH)释放和丙二醛(MDA)水平,呈浓度依赖性。此外,BEG 还增加了细胞超氧化物歧化酶(SOD)活性。此外,我们发现 HO 降低了 Akt 和 eNOS 的磷酸化,这可能间接降低了一氧化氮(NO)的产生。然而,HO 引起的这些作用被 BEG 的预处理所减弱。BEG 的作用被 PI3K 抑制剂(wortmannin)和 eNOS 抑制剂(L-NAME)所抑制。综上所述,本研究表明 BEG 具有抗氧化活性。此外,BEG 通过抗氧化和 PI3K/Akt/eNOS/NO 信号通路减少了 HO 诱导的内皮细胞损伤。